Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
Summary
MDA uses the Venture Philanthropy program to invest in companies committed to clinical application of high-impact, novel treatments for neuromuscular diseases, including ALS. This funding will support the launch of an ALS early feasibility study (EFS) using PathMakers breakthrough technology for motor neuron hyperexcitability suppression.We are truly grateful and honored to have received the support of MDA through the MVP program as we prepare for the clinical application of our non-invasive approach in ALS, said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker. Our technology works by suppressing overactive spinal motor neurons found in people with ALS and could represent a new therapeutic treatment modality for this devastating disease. With offices in Boston (U.S.) and Paris (France), PathMaker is collaborating with world-class institutions on rapidly bringing to market disruptive products for treating brain and other neurological disorders with high unmet medical need. The MyoRegulator\xae platform is based on PathMakers proprietary technology for suppression of hyperexcitable spinal motor neurons, and is built on pioneering work by Prof. Zaghloul Ahmed, Chairman and Professor in the Department of Physical Therapy and Program in Neuroscience, City University of New York (CUNY)/College of Staten Island (CSI).